- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04484948
Utility of Breath-holding Test in Systemic Sclerosis
Utility of Breath-holding Test for Assessment of Pulmonary Disease Severity in Patients With Systemic Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology with high morbidity and mortality. SSc manifests by fibrosis of skin and internal organs. Although the underlying mechanisms are still subject to investigation, endothelial dysfunction and abnormal immune response are thought to contribute to vascular dysfunction and fibrosis in SSc.
Pulmonary involvement, such as pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) is a major cause of death in SSc. Although the 6MWT is generally used for evaluating PAH and ILD, the utility in SSc is undetermined. Several investigators have found weak or moderate correlations of 6MWT in pulmonary involvement in SSc. The 6MWT is influenced by the status of all organ systems involved in exercise (pulmonary, cardiac, peripheral vascular, neuromuscular unit and muscle metabolism) as well as by specifics of test conditions. There is a pressing need for new, practical method which corroborates the current 6MWT for the evaluation of pulmonary disease severity in SSc.
Breath-holding test (BHT) is one of the most useful methods for assessing the sensitivity of peripheral chemoreflex. Recent studies have demonstrated that BHT was correlated to pulmonary function test. BHT can be safely conducted and doctors handle a medical emergency during test easily as well. Therefore, this study evaluates the utility of BHT as surrogate marker of pulmonary involvement in patients with SSc.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A diagnosis of systemic sclerosis according to 2013 ACR/EULAR criteria
- Must understand and voluntarily sign an informed consent form including writing consent for data protection
Exclusion Criteria:
- The resting oxygen saturation by pulse oximetry < 90% in room air
- Unstable angina or myocardial infarction during the previous month
- Patients considered unable to the breath-holding test or 6 minute walk test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Systemic sclerosis group
Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of breath-holding test with Borg Dyspnea Index
Time Frame: Day 1 at inclusion
|
Borg Scale on a 0-10 point
|
Day 1 at inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of breath-holding time with 6 minute walk test (6MWT) distance
Time Frame: Day 1 at inclusion
|
6MWT distance measured in meters according to American Thoracic Society guidelines
|
Day 1 at inclusion
|
Correlation of breath-holding time with oxygen saturation during 6MWT
Time Frame: Day 1 at inclusion
|
Oxygen saturation monitored by wearable pulse oximeter (Radius PPG™ Tetherless Pulse Oximetry, Masimo Corp., Irvine, CA, USA)
|
Day 1 at inclusion
|
Correlation of breath-holding time with pulmonary function indices
Time Frame: Day 1 at inclusion
|
Pulmonary function indices including FVC (%) and DLCO (%)
|
Day 1 at inclusion
|
Correlation of breath-holding time with data on the echocardiography
Time Frame: Day 1 at inclusion
|
Echocardiography including left ventricular ejection fraction and pulmonary arterial systolic pressure (mmHg)
|
Day 1 at inclusion
|
Correlation of breath-holding time with scleroderma health assessment questionnaire (SHAQ)
Time Frame: Day 1 at inclusion
|
SHAQ ranging from 0 to 3
|
Day 1 at inclusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of oxygen saturation during breath-holding test
Time Frame: Day 1 at inclusion
|
Oxygen saturation monitored by radius or forehead pulse oximeter (Masimo Corp., Irvine, CA, USA)
|
Day 1 at inclusion
|
Changes of oxygen saturation during of 6MWT
Time Frame: Day 1 at inclusion
|
Oxygen saturation monitored by wearable pulse oximeter (Radius PPG™ Tetherless Pulse Oximetry, Masimo Corp., Irvine, CA, USA)
|
Day 1 at inclusion
|
Responsiveness of breath-holding test
Time Frame: Month 6 at inclusion
|
Correlation of Δbreath-holding test and ΔPulmonary function indices after 6months
|
Month 6 at inclusion
|
Reliability of breath-holding test
Time Frame: Day 1, and Day 7~Day14 at inclusion
|
Additional 30 patients collection for test-retest reliability
|
Day 1, and Day 7~Day14 at inclusion
|
Development of the machine learning model to predict pulmonary parameters
Time Frame: Year 2 at inclusion
|
Developing two cohorts: Cohort 1 for training a ML model and internal validation; and Cohort 2 for external validation
|
Year 2 at inclusion
|
Collaborators and Investigators
Investigators
- Study Director: Jina Yeo, MD, Seoul National University College of Medicine
- Principal Investigator: Eun Bong Lee, MD PhD, Seoul National University College of Medicine
Publications and helpful links
General Publications
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. Erratum In: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.
- Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011 Apr;40(2):78-83. doi: 10.1007/s12016-010-8198-y.
- Morelli S, Ferrante L, Sgreccia A, Eleuteri ML, Perrone C, De Marzio P, Balsano F. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. Scand J Rheumatol. 2000;29(4):236-42. doi: 10.1080/030097400750041389.
- Vandecasteele E, De Pauw M, De Keyser F, Decuman S, Deschepper E, Piette Y, Brusselle G, Smith V. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. Int J Cardiol. 2016 Jun 1;212:265-73. doi: 10.1016/j.ijcard.2016.03.084. Epub 2016 Mar 25.
- Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v68-9. doi: 10.1093/rheumatology/ken273.
- Yeo J, Kim JY, Kim MH, Park JW, Park JK, Lee EB. Utility of the breath-holding test in patients with systemic sclerosis. Rheumatology (Oxford). 2022 Oct 6;61(10):4113-4118. doi: 10.1093/rheumatology/keac020.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-2006-054-1131
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
University Hospital, Strasbourg, FranceRecruitingJuvenile Systemic SclerosisFrance
Clinical Trials on scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT
-
Yale UniversityFood and Drug Administration (FDA)Active, not recruitingQuality of Life | Lymphoma | Cancer, Breast | Physical Function | Patient Empowerment | Patient EducationUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell NeoplasmUnited States
-
University Hospital Center of MartiniqueInstitut National de la Santé Et de la Recherche Médicale, France; Clinique...RecruitingFever | Dengue | Chikungunya | Zika VirusFrance, French Guiana, Guadeloupe, Martinique, Réunion
-
University Hospital, Clermont-FerrandCompletedLiver Transplantation | Health LiteracyFrance
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Myeloproliferative Neoplasm | Chronic Myelogenous Leukemia...United States
-
National Institute of Medical Sciences and Nutrition...Recruiting
-
UNC Lineberger Comprehensive Cancer CenterCompletedHead and Neck CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingStage IV Prostate Cancer AJCC v7 | Stage IIA Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage I Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7 | Stage II Prostate Cancer AJCC v7United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedBladder CancerUnited States